Prostate‐specific antigen in screening of prostate cancer

Abstract

Prostate-specific antigen (PSA) is a well-characterized human prostate-specific glycoprotein. PSA has been shown to be the most effective immunohistologic marker for prostate cancer, as well as the most useful serologic test in staging and monitoring prostate cancer and in early detection of recurrent disease. The greatest clinical value of PSA is an aid for early detection of prostate cancer. Recent studies have indicated that PSA-based screening of the older population for organ-confined early-stage prostate cancer is an acceptable, practical, and reliable modality. The accuracy of PSA screening is within the same range as the mammogram. The cost-effectiveness of PSA is comparable to other cancer screening tests. Although the increase in the patient's survival due to PSA-based detection of early prostate cancer remains to be documented, it is generally agreed that the PSA test along with digital rectal examination (DRE) should be included in the annual physical examination for men 50 years of age or older. High-risk men are urged to commence at age 40. Asymptomatic men who have both a negative DRE and normal PSA blood test need only to continue an annual DRE and PSA check-up. Men who have a negative DRE and elevated PSA, and all those who have a suspicious DRE regardless of PSA results, should undergo further diagnostic workup, such as transrectal ultrasonography with biopsy of visible lesions. The cure rate is high with timely treatment, when prostate cancer is detected while still confined to the prostate.

N-Linked Glycosylation Supports Cross-Talk between Receptor Tyrosine Kinases and Androgen Receptor

“…AR activity has been shown to induce ER stress response [10] and N-linked glycosylation occurs in the endoplasmic reticulum and Golgi. In order to determine whether N-linked glycosylation alters AR activity, we evaluated the effect of tunicamycin on the expression of Kallikrein 3 (KLK3), which is a direct AR target protein, and also a well-characterized biomarker for prostate cancer and known glycoprotein [32]. Tunicamycin treatment reduced KLK3 protein by 50% in LNCaP and VCaP cells at 12 hours after addition of tunicamycin (Fig.…”

Carbon Nanotube Amplification Strategies for Highly Sensitive Immunodetection of Cancer Biomarkers

“…30 We first analyzed undiluted calf serum containing different amounts of PSA with the SWNT immunosensors with anti-PSA attached ( Figure 1A). Inhibition of nonspecific binding (NSB) was critical to achieve the best sensitivity and detection limits.…”

Carbon Nanotubes for Electronic and Electrochemical Detection of Biomolecules

“…[31] For this, we chose prostate-specific antigen (PSA), an established biomarker for diagnosing and monitoring prostate cancer. [137,138] PSA was the first cancer biomarker to see wide clinical use, and has been employed for 20 years. It can appear in a "danger zone" of 4−10 ng mL −1 in patient serum up to 5 years before clinical signs of disease, illustrating the usefulness and predictive ability of such biomarker measurements in early cancer detection.…”